J&J/Merck fast-acting ibuprofen
This article was originally published in The Tan Sheet
Executive Summary
OTC joint venture expands worldwide product offerings with Dolormin, a lysenate ibuprofen compound developed by Merck and currently sold in Germany by Merck's Woelm Pharma OTC marketing arm. At an April 27 shareholderss meeting, Merck CEO Roy Vagelos called Germany "the first of many markets" for Dolormin.